A significant number of Parkinson’s disease patients have a mutation of the enzyme Leucine-Rich Repeat Protein Kinase 2 (LRRK2, also known as dardarin). However, little is understood about how it is regulated or functions. In a new paper, researchers demonstrate that a family of proteins, the 14-3-3 proteins, interact with LRRK2.